Biomedical scientist & ocean lover. Into diagnostics, biostatistics, & outcomes-based evidence. Employer: @FoundationATCG Opinions: my own. RT≠endorsement.
San Diego, CA
Joined July 2013
- Tweets2K
- Following912
- Followers574
- Likes4K
Ryon Graf, PhD retweeted
The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s41586-0…
Ryon Graf, PhD retweeted
🚨 New pub: real-world PARP-I response in mCRPC according to DDR alteration status.
Huge credit to 💫 @UMichUrology chief resident (and future @StanfordUrology @SUO_YUO fellow) @TrinerDaniel and the amazing @RyonGraf for all their work on this.
Ryon Graf, PhD retweeted
🚨Happy to share our exciting #ctDNA monitoring research in metastatic NSCLC hot off the press @CCR_AACR 👇aacrjournals.org/clincancerr… @MoffittNews
Ryon Graf, PhD retweeted
In a letter to @CellPressNews' Cancer Cell, our scientists share new research demonstrating a consistent association between high tumor mutational burden (TMB-H) & outcomes on immune checkpoint inhibitors in patients of European, African & Asian ancestry: bit.ly/41sICaa
Ryon Graf, PhD retweeted
OS data from PROPEL (Olaparib + Abi) in 1st line mCRPC. 7 mo median OS benefit (p=0.054). But really driven by HRRm subgroup, right? #GU23
Ryon Graf, PhD retweeted
@Ecastromarcos @ASCO #GU23 discussing Talapro-2 & Triton-3 abstracts. Ongoing Qs/challenges:
1. Where will PARPi best fit ? 1L mCRPC? 2L mCRPC? mHSPC?
2. Which pts? BRCA? All-comers?
3. Managing toxicities eg anemia
4. Overcoming resistance eg reversion mutations
Ryon Graf, PhD retweeted
Beautiful summary of mCRPC treatment options with recommended algorithms by @Silke_Gillessen #GU23
Ryon Graf, PhD retweeted
Amazing data presented from Talapro-2 by @neerajaiims on the heals of Propel and Magnitude providing future support of PARPi + ARSI. Trials not powered for OS so leaves some open questions.@ASCO #GU23
Ryon Graf, PhD retweeted
Surprised to hear such emphatic support of PFS wout OS benefit for PARPi in #prostatecancer when 1 in 4 on PARPi require one or more blood transfusions. Not sure that's a fair ask of @reccross or sustainable at a public health level #GU23 Appreciate @Ecastromarcos counterpoint
Ryon Graf, PhD retweeted
Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed rucaparib alone ⬆️ rPFS, particularly in BRCAs. ATM fails to enrich again. OS not +ve yet in either. The biomarker is important for PARPi in CRPC IMO #ASCOGU23
Ryon Graf, PhD retweeted
@Ecastromarcos delivers an elegant &
thoughtful discussion of TALAPRO2 @neerajaiims and TRITON3 @AlanBryce9
We need to understand benefit, ideally need OS benefit before using in HRR beg mCRPC pts, Toxicity can be an issue. #GU23 @ASCO
Ryon Graf, PhD retweeted
Important take home slide from @Ecastromarcos on PARPi role in mCRPC.
BRCA>HRRm>all comers>non-HRRm
#GU23
Ryon Graf, PhD retweeted
👀 Check out what’s popular this week in #JCOPO:
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 👉 fal.cn/3t8RC @HatimHusainMD @geoff_oxnard #ctDNA #lcsm
Ryon Graf, PhD retweeted
Study shows that plasma cfDNA tumour fraction is a pragmatic, independent prognostic biomarker across across pts with mCRPC, mBC, advanced-stage NSCLC and mCRC, with the potential to guide clinical conversations around expected treatment outcomes: annalsofoncology.org/article…
Ryon Graf, PhD retweeted
This article in Annals of Oncology reports on the prognostic value of ctDNA fraction across different tumor types using real-world data from a de-identified clinico-genomic database
annalsofoncology.org/article…
@RyonGraf @ReichertMedOnc @geoff_oxnard @wandering_gu @StoverLab
Ryon Graf, PhD retweeted
Loving John Smoltz’s on-air hat tip to the late Tony Gwynn. I knew Gwynn did well against that Braves Hall of Fame ‘90s rotation, but I had no idea the numbers were this ridiculous. He was the best. RIP. #Padres – at Los Angeles, CA
Ryon Graf, PhD retweeted
Great collab evaluating hypothesis that ctDNA tumor fraction may be prognostic across cancers.
Full 🧵to follow!
What a team! Z Reichert @wandering_gu @UMRogelCancer, E. Castellanos et al @flatironhealth, @geoff_oxnard @RyonGraf @FoundationATCG @OSUCCC_James
h/t @PTarantinoMD!
Can we distinguish aggressive metastatic tumors from more indolent ones with a blood draw? Just out on @Annals_Oncology an interesting analysis by @StoverLab & colleagues, which found a strong prognostic value for ctDNA-derived tumor fraction.
annalsofoncology.org/article…
Ryon Graf, PhD retweeted
@GUONCGarciaJA gives a shoutout to @neerajaiims @umangtalking on their work on #SPOP mutations as a predictive biomarker in mHSPC @OncLiveSOSS @RyonGraf @MosheOrnsteinMD @ChrisWeeMD @DrOmarMian @EAntonarakis
Ryon Graf, PhD retweeted
About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot
Ryon Graf, PhD retweeted
Ever since #ESMO22 @myESMO I have been seeing #ChalabiPlot all over. Found this one and the likely EFS curve in the woodpile. @MyriamChalabi @OncoAlert
